Envisia Therapeutics, Liquidia ophthalmic news

Liquidia spun out its ophthalmology programs into Envisia. The newco's lead program is ENV515, an extended-release formulation of an undisclosed prostaglandin analogue in preclinical development to reduce intraocular pressure (IOP) in glaucoma patients. The newco plans to start Phase I testing by mid-2014. Envisia also has rights to Liquidia's Particle Replication in Non-Wetting Templates (PRINT) drug delivery technology, but the companies are not disclosing the terms of the license. Envisia is using the technology to develop a pipeline of small and large molecule ocular therapies. In May, Liquidia said it planned to form a new ophthalmic company (see BioCentury, May 13). ...